Revolution Medicines, Inc. (RVMD)
| Market Cap | 31.78B +322.5% |
| Revenue (ttm) | n/a |
| Net Income | -1.37B |
| EPS | -7.12 |
| Shares Out | 212.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,804,796 |
| Open | 150.00 |
| Previous Close | 149.94 |
| Day's Range | 146.50 - 150.79 |
| 52-Week Range | 34.00 - 155.70 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 144.53 (-3.31%) |
| Earnings Date | May 6, 2026 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $144.53, which is a decrease of -3.31% from the latest price.
News
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await what they hope will be a spee...
Revolution Medicines price target raised to $185 from $170 at BofA
BofA analyst Alex Stranahan raised the firm’s price target on Revolution Medicines (RVMD) to $185 from $170 and keeps a Buy rating on the shares. The Q1 report “largely reinforced…
Revolution Medicines price target raised to $172 from $120 at Piper Sandler
Piper Sandler analyst Kelsey Goodwin raised the firm’s price target on Revolution Medicines (RVMD) to $172 from $120 and keeps an Overweight rating on the shares. The firm notes the…
Revolution Medicines price target raised to $205 from $175 at Guggenheim
Guggenheim raised the firm’s price target on Revolution Medicines (RVMD) to $205 from $175 and keeps a Buy rating on the shares after the company reported Q1 results and highlighted…
Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)
Cash, cash equivalents and marketable securities were $1.9B as of March 31. In April, the company received $2.1B in net proceeds from concurrent financings. “Last month we reported positive results…
Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B
Revolution Medicines (RVMD) updated its FY26 GAAP operating expenses guidance to a range of $1.7B-$1.8B. The expected increase in operating expenses is due to higher projected non-cash stock-based com...
Revolution Medicines announces NEJM publication of data on Daraxonrasib
The company states: “Revolution Medicines (RVMD) announced that The New England Journal of Medicine, NEJM, has published a report describing data from the Phase 1/2 clinical trial evaluating daraxonra...
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer Data contributed to the scien...
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
An experimental drug from Revolution Medicines that nearly doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate of mostly low-grade side effects...
Revolution Medicines Earnings Call Transcript: Q1 2026
Daraxonrasib demonstrated unprecedented survival benefits in pancreatic cancer, driving strong investor support and a $2 billion capital raise. Multiple registrational trials are underway across pancreatic, lung, and colorectal cancers, with robust financial resources and global commercialization plans in place.
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary p...
US FDA authorizes early access to Revolution's pancreatic cancer pill
The U.S. Food and Drug Administration has authorized the granting of early access before regulatory approval to Revolution Medicines' pill for patients with previously treated pancreatic cancer, the...
FDA permits expanded access for Revolution pancreatic cancer drug
The Food and Drug Administration isaid it issued a “safe to proceed” letter to Revolution Medicines (RVMD), allowing the company to initiate an expanded access treatment protocol for its experimental…
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
There's a Revolution in Cancer. But Can Big Pharma Afford It?
Revolution Medicines' stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.
Erasca believes Revolution infringement claims ‘without merit,’ says Stifel
Stifel spoke with Erasca (ERAS) management this morning after the company disclosed that it received a letter from legal counsel for Revolution Medicines (RVMD) alleging that ERAS-0015 infringes certa...
Erasca sinks after Revolution Medicines alleges patent infringement
Erasca (ERAS) announced that it received a letter from legal counsel for Revolution Medicines (RVMD). In the letter Revolution alleged that Erasca’s asset ERAS-0015 is “substantially equivalent” to ce...
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Two experimental drugs showed striking early results against pancreatic cancer
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colore...
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Revolution Medicines to present updated Phase 1 data for zoldonrasib
Revolution Medicines (RVMD) announced updated Phase 1 clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer,...
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
This Pill May Help Pancreatic Cancer Patients Live Longer
In this week's edition of InnovationRx, we look at Revolution Medicine's pancreatic cancer pill, the top self-made healthcare entrepreneurs, the latest 30 Under 30 Science & Healthcare list, and more....